Trypanosomiasis, African clinical trials
The registry lists 26 studies for Trypanosomiasis, African across more than 10 countries. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-04-06.
Get an email when these change. Save the Trypanosomiasis, African studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Drugs for Neglected Diseases (16) · Institut de Recherche pour le Developpement (4) · Immtech Pharmaceuticals, Inc (2) · Epicentre (2) · Institute of Tropical Medicine, Belgium (1) · Foundation for Innovative New Diagnostics, Switzerland (1)
What is being tested here
Drugs under test in Trypanosomiasis, African studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| SCYX 7158 | 0 | 3 | 5 |
| Fexinidazole | 0 | 3 | 4 |
| Nifurtimox | 0 | 2 | 2 |
| Pafuramidine | 0 | 0 | 2 |
| Eflornithine | 0 | 1 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Dec 2026Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT) · Phase 3 · Drugs for Neglected Diseases
Who these studies take
No Trypanosomiasis, African study is recruiting now.
Across all 26 studies, recruiting or not: 35% stop at 75 or younger and 31% at 65; 81% take children; 0% are for women only and 19% for men only; 31% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 26 of 26. search them.
- Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)Not yet recruitingNCT06356974Phase 3
- Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric PatientsCompletedNCT05433350Phase 2/32 countries
- Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. GambienseCompletedNCT03087955Phase 2/32 countries
- Safety and Tolerability Study of Acoziborole in g-HAT Seropositive SubjectsCompletedNCT05256017Phase 2/32 countries
- Fexinidazole in Human African Trypanosomiasis Due to T. b. RhodesienseCompletedNCT03974178Phase 2/32 countries
- Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any StageCompletedNCT03025789Phase 32 countries
- Prospective Evaluation of the Specificity of Serological Tests for Human African TrypanosomiasisCompletedNCT05466630Not applicable2 countries
- Screen and Treat Implementation for HAT ControlWithdrawnNCT05645822
- Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum MalariaWithdrawnNCT03394976
- DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and DextromethorphanCompletedNCT05947604Phase 11 country
- Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination MonitoringCompletedNCT04099628Not applicable3 countries
- ADME Study of Acoziborole in Healthy SubjectsCompletedNCT04270981Phase 11 country
- Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case DetectionCompletedNCT03356665Not applicable3 countries
- Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cureCompletedNCT03112655Not applicable1 country
- Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal StudyCompletedNCT02169557Phase 2/31 country
- Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal StudyCompletedNCT02184689Phase 2/31 country
- Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2CompletedNCT01685827Phase 2/33 countries
- Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With FoodTerminatedNCT01483170Phase 11 country
- Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African TrypanosomiasisCompletedNCT00146627Phase 32 countries
- Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market FormulationCompletedNCT02571062Phase 11 country
- Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158CompletedNCT01533961Phase 11 country
- Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic PhaseCompletedNCT00906880Phase 41 country
- Trial of DB289 for the Treatment of Stage I African TrypanosomiasisCompletedNCT00803933Phase 21 country
- A Trial of DB289 for the Treatment of Stage I African TrypanosomiasisCompletedNCT00802594Phase 22 countries
- Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, UgandaTerminatedNCT00489658Phase 2/31 country
- Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African TrypanosomiasisTerminatedNCT00330148Phase 31 country